No Survival Benefit from Lymph Node Dissection in Biopsy-Positive Melanoma
In sentinel node biopsy (SLNB)-positive melanoma, no survival benefit was achieved by complete lymph node dissection (CLND).
ASCO 2015
Bortezomib Consolidation More Effective Than Observation for Newly Diagnosed Multiple Myeloma
Bortezomib consolidation significantly improved progression-free survival compared with observation in multiple myeloma.
Daratumumab Provides Durable Activity in Heavily Pre-Treated Multiple Myeloma
Daratumumab demonstrated profound durable activity with meaningful responses in patients with heavily pretreated multiple myeloma.
Efficacy of Chemotherapy Similar to Radiotherapy for Anaplastic Glioma
Long-term data do not support efficacy of primary temozolomide monotherapy versus radiotherapy in anapestic glioma.
Tumor Treating Fields Improve Survival in Newly Diagnosed Glioblastoma
Tumor Treating Fields improved progression-free survival and overall survival in patients with newly diagnosed glioblastoma.
Worse Outcomes in Patients Managed Without Radiotherapy After Chemo for Breast Cancer
Patients managed without radiotherapy after neoadjuvant chemotherapy for breast cancer have a significantly worse outcome.
Etirinotecan Pegol Benefits Patients with Advanced Breast Cancer
Etirinotecan pegol provided a clinically meaningful benefit to patients with late-stage advanced breast cancer.
Pembrolizumab Immunotherapy Effective in Recurrent, Metastatic Head and Neck Cancer
Pembrolizumab immunotherapy is effective in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Panitumumab, Accelerated Fractionation RX Not Superior to Standard of Care in Head and Neck Cancer
Panitumumab plus accelerated fractionation radiotherapy (AFX) was not superior in squamous cell carcinoma of the head and neck.
Complete Response Rate at 30 Months Correlates with Progression-Free Survival in Follicular Lymphoma
Complete response rate at 30 months is a surrogate endpoint for progression-free survival in first-line follicular lymphoma trials.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2015
Loading... 
Loading...